Biogen Inc. (NASDAQ:BIIB) is one of the best performing pharma stocks in 2025. Biogen Inc. (NASDAQ:BIIB) received several rating updates on January 8. Truist lifted the price target on the stock to $190 from $142 but maintained a Hold rating, telling investors in a research note that while it updated its model, the fundamental views remain the same as 2025.
The same day, Biogen Inc. (NASDAQ:BIIB) also received rating updates from Goldman Sachs and Mizuho. Goldman Sachs raised the price target on the stock to $225 from $197 while keeping a Buy rating on the shares. It expects momentum to continue in 2026 after strong sector performance in 2025, supported by improving fundamentals, market dynamics, and easing policy risks. These factors, along with their secondary effects such as M&A, persist, according to the firm.
Mizuho, on the other hand, lifted the price target on Biogen Inc. (NASDAQ:BIIB) to $207 from $177 and maintained an Outperformed rating, stating that it updated the company’s model since 2026 is “looking a bit better” for Biogen Inc. (NASDAQ:BIIB).
Biogen Inc. (NASDAQ:BIIB) is a global biopharmaceutical company that discovers, develops, and delivers advanced therapies for serious diseases across the globe. Its medicine portfolio treats multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer’s disease, and amyotrophic lateral sclerosis (ALS). The company has an elaborate marketed product portfolio for MS, including TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA. It also markets SPINRAZA to treat SMA, SKYCLARYS for the treatment of Friedreich’s Ataxia, and other drugs.
While we acknowledge the potential of BIIB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
-1024x683.jpg "The Platner Problem: Is Political Vetting Broken?")
